Incannex Healthcare Limited (IXHL)
USD 0.65
(3.34%)
USD 0.65
(3.34%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 17.04 Million USD | -28.32% |
| 2023 | 58.64 Million AUD | 125.04% |
| 2022 | 26.05 Million AUD | 271.77% |
| 2021 | 7 Million AUD | 140.8% |
| 2020 | 2.91 Million AUD | 462.01% |
| 2019 | 517.91 Thousand AUD | -26.83% |
| 2018 | 707.85 Thousand AUD | -29.25% |
| 2017 | 1 Million AUD | 120.28% |
| 2016 | 454.22 Thousand AUD | -92.71% |
| 2015 | 6.23 Million AUD | -19.57% |
| 2014 | 7.74 Million AUD | -60.02% |
| 2013 | 19.38 Million AUD | -18.49% |
| 2012 | 23.78 Million AUD | 18.42% |
| 2011 | 20.08 Million AUD | 25.23% |
| 2010 | 16.03 Million AUD | 9.53% |
| 2009 | 14.64 Million AUD | 38.46% |
| 2008 | 10.57 Million AUD | 55.17% |
| 2007 | 6.81 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 22.35 Million USD | -5.99% |
| 2024 Q3 | 17.25 Million USD | -22.85% |
| 2024 Q4 | 17.04 Million USD | -23.76% |
| 2023 Q4 | 58.64 Million AUD | 0.0% |
| 2023 FY | 58.64 Million AUD | 125.04% |
| 2023 Q2 | 64.77 Million AUD | 0.0% |
| 2022 Q2 | 20.01 Million AUD | 0.0% |
| 2022 FY | 26.05 Million AUD | 271.77% |
| 2022 Q4 | 37.87 Million AUD | 0.0% |
| 2021 Q2 | 12.18 Million AUD | 0.0% |
| 2021 Q4 | 9.32 Million AUD | 0.0% |
| 2021 FY | 7 Million AUD | 140.8% |
| 2020 Q2 | 5.59 Million AUD | 0.0% |
| 2020 FY | 2.91 Million AUD | 462.01% |
| 2020 Q4 | 4.23 Million AUD | 0.0% |
| 2019 FY | 517.91 Thousand AUD | -26.83% |
| 2019 Q4 | 517.91 Thousand AUD | 0.0% |
| 2019 Q2 | 888.04 Thousand AUD | 0.0% |
| 2018 FY | 707.85 Thousand AUD | -29.25% |
| 2018 Q2 | 1.12 Million AUD | 0.0% |
| 2018 Q4 | 707.85 Thousand AUD | 0.0% |
| 2017 FY | 1 Million AUD | 120.28% |
| 2017 Q4 | 1 Million AUD | 0.0% |
| 2017 Q2 | 2.64 Million AUD | 0.0% |
| 2016 Q4 | 454.22 Thousand AUD | 300.0% |
| 2016 FY | 454.22 Thousand AUD | -92.71% |
| 2016 Q3 | 113.55 Thousand AUD | -89.86% |
| 2016 Q2 | 1.11 Million AUD | -28.14% |
| 2016 Q1 | 1.55 Million AUD | -75.0% |
| 2015 Q1 | 1.93 Million AUD | -75.0% |
| 2015 Q4 | 6.23 Million AUD | 300.0% |
| 2015 Q2 | 8.48 Million AUD | 338.13% |
| 2015 Q3 | 1.55 Million AUD | -81.64% |
| 2015 FY | 6.23 Million AUD | -19.57% |
| 2014 FY | 7.74 Million AUD | -60.02% |
| 2014 Q1 | 4.84 Million AUD | -75.0% |
| 2014 Q2 | 18.76 Million AUD | 287.27% |
| 2014 Q3 | 1.93 Million AUD | -89.68% |
| 2014 Q4 | 7.74 Million AUD | 300.0% |
| 2013 FY | 19.38 Million AUD | -18.49% |
| 2013 Q4 | 19.38 Million AUD | 300.0% |
| 2013 Q3 | 4.84 Million AUD | -82.59% |
| 2013 Q2 | 27.82 Million AUD | 368.06% |
| 2013 Q1 | 5.94 Million AUD | -75.0% |
| 2012 Q2 | 22.85 Million AUD | 355.18% |
| 2012 FY | 23.78 Million AUD | 18.42% |
| 2012 Q4 | 23.78 Million AUD | 300.0% |
| 2012 Q3 | 5.94 Million AUD | -73.98% |
| 2012 Q1 | 5.02 Million AUD | -75.0% |
| 2011 Q1 | 4 Million AUD | -75.0% |
| 2011 Q4 | 20.08 Million AUD | 300.0% |
| 2011 FY | 20.08 Million AUD | 25.23% |
| 2011 Q3 | 5.02 Million AUD | -74.02% |
| 2011 Q2 | 19.32 Million AUD | 382.04% |
| 2010 Q4 | 16.03 Million AUD | 300.0% |
| 2010 Q2 | 15.09 Million AUD | 312.42% |
| 2010 Q1 | 3.66 Million AUD | -75.0% |
| 2010 FY | 16.03 Million AUD | 9.53% |
| 2010 Q3 | 4 Million AUD | -73.44% |
| 2009 Q4 | 14.64 Million AUD | 300.0% |
| 2009 Q3 | 3.66 Million AUD | 1363.71% |
| 2009 Q2 | 250.08 Thousand AUD | -90.54% |
| 2009 FY | 14.64 Million AUD | 38.46% |
| 2009 Q1 | 2.64 Million AUD | -75.0% |
| 2008 Q2 | 6.65 Million AUD | 290.64% |
| 2008 Q4 | 10.57 Million AUD | 300.0% |
| 2008 FY | 10.57 Million AUD | 55.17% |
| 2008 Q1 | 1.7 Million AUD | -75.0% |
| 2008 Q3 | 2.64 Million AUD | -60.28% |
| 2007 FY | 6.81 Million AUD | 0.0% |
| 2007 Q4 | 6.81 Million AUD | 300.0% |
| 2007 Q3 | 1.7 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 98.509% |
| Embecta Corp. | 1.21 Billion USD | 98.596% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 98.115% |
| Dynavax Technologies Corporation | 997.09 Million USD | 98.29% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 91.717% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 98.917% |
| PainReform Ltd. | 9.93 Million USD | -71.672% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 70.311% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 37.664% |
| SCYNEXIS, Inc. | 128.41 Million USD | 86.725% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | 26.29% |
| Cosmos Health Inc. | 66.29 Million USD | 74.286% |
| Journey Medical Corporation | 76.84 Million USD | 77.818% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 37.664% |
| Safety Shot Inc | 12.7 Million USD | -34.131% |
| Alpha Teknova, Inc. | 128.58 Million USD | 86.743% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 97.659% |
| Bright Green Corporation | 17.4 Million USD | 2.046% |
| Procaps Group, S.A. | 460.18 Million USD | 96.296% |
| Theratechnologies Inc. | 77.76 Million USD | 78.08% |
| Harrow Health, Inc. | 311.75 Million USD | 94.532% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -14.463% |
| Biofrontera Inc. | 27.93 Million USD | 38.97% |
| DURECT Corporation | 45.18 Million USD | 62.276% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 98.79% |
| Cronos Group Inc. | 1.13 Billion USD | 98.497% |
| OptiNose, Inc. | 107.72 Million USD | 84.176% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 96.381% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 69.531% |
| RedHill Biopharma Ltd. | 23.04 Million USD | 26.034% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 96.294% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -43.034% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 79.154% |
| Radius Health, Inc. | 1.71 Billion USD | 99.007% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 68.009% |
| ProPhase Labs, Inc. | 91.92 Million USD | 81.456% |
| Phibro Animal Health Corporation | 982.18 Million USD | 98.264% |
| Procaps Group S.A. | 460.18 Million USD | 96.296% |
| Alvotech | 950.09 Million USD | 98.206% |
| TherapeuticsMD, Inc. | 43.3 Million USD | 60.639% |
| Viatris Inc. | 47.68 Billion USD | 99.964% |
| Rockwell Medical, Inc. | 52.17 Million USD | 67.326% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 85.565% |
| SIGA Technologies, Inc. | 254.83 Million USD | 93.311% |
| Tilray Brands, Inc. | 4.33 Billion USD | 99.607% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 93.772% |
| Shineco, Inc. | 84.17 Million USD | 79.749% |
| PetIQ, Inc. | 868.22 Million USD | 98.037% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -102.021% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.476% |
| Alimera Sciences, Inc. | 153.52 Million USD | 88.896% |
| Silver Spike Investment Corp. | 88.57 Million USD | 80.754% |
| Assertio Holdings, Inc. | 286.41 Million USD | 94.048% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -186.421% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | 49.559% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | 45.437% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -28.681% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 93.472% |
| Hempacco Co., Inc. | 18.04 Million USD | 5.521% |
| Talphera, Inc. | 20.39 Million USD | 16.416% |
| Alvotech | 950.09 Million USD | 98.206% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 95.803% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 98.968% |
| Currenc Group, Inc. | 141.49 Million USD | 87.952% |
| Kamada Ltd. | 351.96 Million USD | 95.157% |
| Indivior PLC | 1.95 Billion USD | 99.126% |
| Evoke Pharma, Inc. | 7.06 Million USD | -141.167% |
| Flora Growth Corp. | 23.62 Million USD | 27.846% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -28.681% |
| Evolus, Inc. | 188.99 Million USD | 90.98% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 98.668% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 98.873% |
| Akanda Corp. | 8.83 Million USD | -92.84% |